Myelofibrosis: molecular and cell biological aspects

[1]  H. Kreipe,et al.  Aberrant proplatelet formation in chronic myeloproliferative neoplasms. , 2010, Leukemia research.

[2]  N. Kröger,et al.  Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) — a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia , 2010, Annals of Hematology.

[3]  H. Kreipe,et al.  JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. , 2009, Experimental hematology.

[4]  N. Kröger,et al.  Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis , 2009, British journal of haematology.

[5]  P. Campbell,et al.  Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Gratwohl,et al.  The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders , 2008, Haematologica.

[7]  H. Kreipe,et al.  Expression profiling of apoptosis-related genes in megakaryocytes: BNIP3 is downregulated in primary myelofibrosis. , 2008, Experimental hematology.

[8]  B. Wiese,et al.  Growth Factors , Cytokines , Cell Cycle Molecules Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines , 2010 .

[9]  B. Wiese,et al.  Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. , 2006, The American journal of pathology.

[10]  Joseph E Italiano,et al.  The biogenesis of platelets from megakaryocyte proplatelets. , 2005, The Journal of clinical investigation.

[11]  B. Wiese,et al.  Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin , 2005, British journal of haematology.

[12]  H. Kreipe,et al.  Aberrant expression of transforming growth factor β‐1 (TGFβ‐1) per se does not discriminate fibrotic from non‐fibrotic chronic myeloproliferative disorders , 2005 .

[13]  H. Kreipe,et al.  Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. , 2005, Journal of Pathology.

[14]  H. Kreipe,et al.  Aberrant expression of platelet-derived growth factor (PDGF) and PDGF receptor-alpha is associated with advanced bone marrow fibrosis in idiopathic myelofibrosis. , 2005, Haematologica.

[15]  W. Vainchenker,et al.  Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. , 2002, Blood.

[16]  U. Lehmann,et al.  Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression. , 2002, Blood.

[17]  J. Thiele,et al.  Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis. , 1997, Acta haematologica.

[18]  H. Kreipe,et al.  Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. , 1991, Blood.

[19]  T. D. Hamilton,et al.  Classification of Tumours , 1930, Edinburgh medical journal.